Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002 An Open-Label Safety and Efficacy Study of Reslizumab(CTx55700) for the Treatment of Pediatric Subje ...
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Efficacy and Safety Study of Reslizumabto Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Ye ...
An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years An Efficacy and Safety Study of Reslizumab(CTx55700) in the Treatment of Eosinophilic Esophagitis in ...